Incyte Corporation

Organisation

1801 Augustine Cut-Off, Wilmington, DE, United States, 19803

Headquarters

2844

Employees

Health Technology

Industry

Herve Hoppenot

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF;  INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Price

Target

Incyte Corporation (INCY) Price vs Consensus Price Target

As per the chart shown above, analysts believe that the Incyte Corporation (INCY) share price will touch around $107.14 in next 12-months.

Currently 29 wall-street analysts regularly analyze the financials of Incyte Corporation on a frequent basis to provide recommendations along with target share price. 29 analysts offering 12-month price forecasts for Incyte Corporation (INCY) have a share price target of $107.14. This median of share price forecast represents a 11.68% upside from the latest price of $95.93 as on 05.04.26.

Incyte Corporation (INCY) Share Price Forecast

Home

US Stocks

Incyte Corporation (INCY)

Incyte Corporation Stock Forecast

Incyte Corporation Stock Forecast & Price Target (Analyst Recommendation) | INDmoney

Percentage Difference

Incyte Corporation (INCY): Difference between Current Price & Median Forecasted Price

Below is a chart showing the percentage difference between Incyte Corporation's share price and its median forecast price. As on 05.04.26, the difference is -11.98%

Incyte Corporation Forecast and Target Price

Incyte Corporation (INCY) Share Price Forecast

Incyte Corporation (INCY) Price vs Consensus Price Target

Incyte Corporation (INCY) Share Price Forecast v/s Share Price Today

Incyte Corporation (INCY): Difference between Current Price & Median Forecasted Price

Incyte Corporation (INCY) Share Price Technical Analysis

50 Day Moving Average v/s Current Share Price

200 Day Moving Average v/s Current Share Price